{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:41:39Z","timestamp":1780735299012,"version":"3.54.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","amjmedsci.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.amjms.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T16:32:05Z","timestamp":1718209925000},"page":"446-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cyclophosphamide in refractory autoimmune hepatitis and autoimmune hepatitis coexisting extrahepatic autoimmune disorders"],"prefix":"10.1016","volume":"368","author":[{"given":"AnJi","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SuTing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoYan","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuFeng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.amjms.2024.06.007_bib0001","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.amjms.2024.06.007_bib0002","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5009\/gnl19261","article-title":"Autoimmune hepatitis: 2019 update","volume":"14","author":"Tanaka","year":"2020","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.amjms.2024.06.007_bib0003","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhep.2010.12.012","article-title":"Autoimmune hepatitis","volume":"55","author":"Lohse","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjms.2024.06.007_bib0004","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","article-title":"Autoimmune hepatitis","volume":"4","author":"Mieli-Vergani","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.amjms.2024.06.007_bib0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00281-022-00937-5","article-title":"B cells in autoimmune hepatitis: bystanders or central players?","volume":"44","author":"Schulthei\u00df","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"1","key":"10.1016\/j.amjms.2024.06.007_bib0006","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jhep.2009.10.016","article-title":"Immune-mediated liver injury","volume":"52","author":"Lohse","year":"2010","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.amjms.2024.06.007_bib0007","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00535-011-0421-y","article-title":"Present status of autoimmune hepatitis in Japan: a nationwide survey","volume":"46","author":"Abe","year":"2011","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.amjms.2024.06.007_bib0008","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2015.07.017","article-title":"Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy","volume":"14","author":"Muratori","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MPG.0000000000000593","article-title":"Fulminant hepatic failure of autoimmune aetiology in children","volume":"60","author":"Di Giorgio","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.amjms.2024.06.007_bib0010","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/MEG.0000000000000353","article-title":"Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure","volume":"27","author":"Mendizabal","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.amjms.2024.06.007_bib0011","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/MCG.0000000000000805","article-title":"Natural History and Treatment Outcomes of Severe Autoimmune Hepatitis","volume":"51","author":"Sonthalia","year":"2017","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.amjms.2024.06.007_bib0012","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/egh.09.15","article-title":"Current and future treatments of autoimmune hepatitis","volume":"3","author":"Czaja","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1 Suppl","key":"10.1016\/j.amjms.2024.06.007_bib0013","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune hepatitis\u2013Update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.amjms.2024.06.007_bib0014","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and Children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.amjms.2024.06.007_bib0016","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/j.1572-0241.2008.01922.x","article-title":"Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis","volume":"103","author":"Montano-Loza","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0017","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hep.1840150208","article-title":"Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis","volume":"15","author":"Sanchez-Urdazpal","year":"1992","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.amjms.2024.06.007_bib0018","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/apt.12042","article-title":"Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs","volume":"36","author":"Selvarajah","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0019","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/jhep.2002.34944","article-title":"Diagnosis and treatment of autoimmune hepatitis","volume":"36","author":"Czaja","year":"2002","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.amjms.2024.06.007_bib0020","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3748\/wjg.14.3388","article-title":"Transplantation in autoimmune liver diseases","volume":"14","author":"Mottershead","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"4 Pt 1","key":"10.1016\/j.amjms.2024.06.007_bib0021","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/jhep.2000.16666","article-title":"Liver transplantation for autoimmune hepatitis","volume":"32","author":"Reich","year":"2000","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0022","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2017.09.063","article-title":"Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy","volume":"16","author":"Roberts","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.amjms.2024.06.007_bib0023","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/1756283X12450251","article-title":"Management of patients with difficult autoimmune hepatitis","volume":"5","author":"Parker","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"10.1016\/j.amjms.2024.06.007_bib0024","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1155\/2008\/509459","article-title":"The use of budesonide in the treatment of autoimmune hepatitis in Canada","volume":"22","author":"Zandieh","year":"2008","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.amjms.2024.06.007_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/00365521.2018.1551498","article-title":"A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis","volume":"54","author":"Hanouneh","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.amjms.2024.06.007_bib0026","first-page":"193","article-title":"Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis: interim analysis report of a randomized controlled trial","volume":"5","author":"Nasseri-Moghaddam","year":"2013","journal-title":"Middle East J Dig Dis"},{"issue":"6","key":"10.1016\/j.amjms.2024.06.007_bib0027","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the International Autoimmune Hepatitis Group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.amjms.2024.06.007_bib0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cgh.2017.08.029","article-title":"Methotrexate in the treatment of autoimmune hepatitis","volume":"16","author":"Efe","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.amjms.2024.06.007_bib0029","first-page":"571","article-title":"Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis\u2013report of three cases","volume":"35","author":"Kanzler","year":"1997","journal-title":"Z Gastroenterol"},{"issue":"6","key":"10.1016\/j.amjms.2024.06.007_bib0030","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4254\/wjh.v6.i6.410","article-title":"Management of autoimmune hepatitis: focus on pharmacologic treatments beyond corticosteroids","volume":"6","author":"Casal Moura","year":"2014","journal-title":"World J Hepatol"},{"issue":"5","key":"10.1016\/j.amjms.2024.06.007_bib0031","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/gut.50.5.713","article-title":"Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin","volume":"50","author":"Zolfino","year":"2002","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.amjms.2024.06.007_bib0032","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","article-title":"Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus","volume":"25","author":"Chatur","year":"2005","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.amjms.2024.06.007_bib0033","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.mcg.0000177260.72692.e8","article-title":"Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease","volume":"39","author":"Czaja","year":"2005","journal-title":"J Clin Gastroenterol"},{"issue":"12","key":"10.1016\/j.amjms.2024.06.007_bib0034","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.amjms.2024.06.007_bib0035","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"10.1016\/j.amjms.2024.06.007_bib0036","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2014.05.003","article-title":"Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study","volume":"4","author":"Jothimani","year":"2014","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.amjms.2024.06.007_bib0037","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","article-title":"The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes","volume":"34","author":"Baven-Pronk","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.amjms.2024.06.007_bib0038","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ki.1986.46","article-title":"The effects of daily cyclophosphamide administration on the development and extent of primary experimental interstitial nephritis in rats","volume":"29","author":"Agus","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2024.06.007_bib0039","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.amjms.2024.06.007_bib0040","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/s-0031-1279825","article-title":"Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment","volume":"32","author":"Lynch","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.amjms.2024.06.007_bib0041","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/ard.2007.077446","article-title":"High-dose cyclophosphamide without stem cell rescue in scleroderma","volume":"67","author":"Tehlirian","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.amjms.2024.06.007_bib0042","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.27371","article-title":"High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial","volume":"62","author":"Petri","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0043","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2002-01-0087","article-title":"High-dose cyclophosphamide for refractory autoimmune hemolytic anemia","volume":"100","author":"Moyo","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.amjms.2024.06.007_bib0044","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.7326\/0003-4819-129-12-199812150-00007","article-title":"Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease","volume":"129","author":"Brodsky","year":"1998","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.amjms.2024.06.007_bib0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2177\/jsci.28.154","article-title":"A case of autoimmune hepatitis needed to be differentiated from EBV hepatitis, in that the histology of liver biopsy specimen was useful for diagnosis","volume":"28","author":"Nakajima","year":"2005","journal-title":"Nihon Rinsh\u014d Men'eki Gakkai kaishi = Japanese journal of clinical immunology"},{"issue":"5","key":"10.1016\/j.amjms.2024.06.007_bib0046","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2001-13708","article-title":"Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience","volume":"39","author":"Kanzler","year":"2001","journal-title":"Z Gastroenterol"},{"issue":"4","key":"10.1016\/j.amjms.2024.06.007_bib0047","first-page":"367","article-title":"A Patient with Type 3 autoimmune polyglandular syndrome who developed systemic lupus erythematosus 8 years after the diagnosis of autoimmune hepatitis","volume":"73","author":"Mifune-Morioka","year":"2019","journal-title":"Acta Med Okayama"},{"issue":"7","key":"10.1016\/j.amjms.2024.06.007_bib0048","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/pbc.21143","article-title":"Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide","volume":"49","author":"Savage","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0049","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jceh.2020.05.009","article-title":"Unusual presentation of systemic lupus erythematosus in a young male: a case report","volume":"11","author":"Praharaj","year":"2021","journal-title":"J Clin Exp Hepatol"},{"issue":"11","key":"10.1016\/j.amjms.2024.06.007_bib0050","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1046\/j.1440-1746.2001.02615.x","article-title":"Long-term outcome of autoimmune hepatitis in children","volume":"16","author":"Saadah","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.amjms.2024.06.007_bib0051","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jpeds.2013.12.008","article-title":"Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis: a population-based study","volume":"164","author":"Deneau","year":"2014","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.amjms.2024.06.007_bib0052","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0053","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00296-018-4189-8","article-title":"Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review","volume":"39","author":"\u00dcsk\u00fcdar Cansu","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.amjms.2024.06.007_bib0054","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-97-1-62","article-title":"Cyclophosphamide heatotoxicity in a patient with systemic lupus erythematosus","author":"Bacon","year":"1982","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00007611-198502000-00034","article-title":"Cyclophosphamide-associated hepatotoxicity","volume":"78","author":"Goldberg","year":"1985","journal-title":"South Med J"},{"issue":"5722","key":"10.1016\/j.amjms.2024.06.007_bib0056","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/bmj.3.5722.588","article-title":"Massive hepatic necrosis after cyclophosphamide","volume":"3","author":"Aubrey","year":"1970","journal-title":"Br Med J"},{"issue":"8","key":"10.1016\/j.amjms.2024.06.007_bib0057","doi-asserted-by":"crossref","first-page":"656","DOI":"10.5812\/kowsar.1735143X.713","article-title":"Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature","volume":"11","author":"Gutkowski","year":"2011","journal-title":"Hepat Mon"},{"issue":"7","key":"10.1016\/j.amjms.2024.06.007_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071542","article-title":"Genetic polymorphism of GSTP-1 affects cyclophosphamide treatment of autoimmune diseases","volume":"25","author":"Hajdin\u00e1k","year":"2020","journal-title":"Molecules"},{"issue":"4877","key":"10.1016\/j.amjms.2024.06.007_bib0059","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1126\/science.2459779","article-title":"Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro","volume":"242","author":"Salahuddin","year":"1988","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.amjms.2024.06.007_bib0060","first-page":"149","article-title":"Hepatotoxicity of cyclophosphamide in man: pharmacokinetic analysis","volume":"61","author":"Honjo","year":"1988","journal-title":"Res Commun Chem Pathol Pharmacol"},{"issue":"1","key":"10.1016\/j.amjms.2024.06.007_bib0061","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1742-7843.2009.00531.x","article-title":"Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy","volume":"107","author":"Afsar","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.amjms.2024.06.007_bib0062","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","article-title":"Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide","volume":"102","author":"Bray","year":"2010","journal-title":"Br J Cancer"},{"issue":"15","key":"10.1016\/j.amjms.2024.06.007_bib0063","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158644","article-title":"Isothiocyanates (ITCs) 1-(Isothiocyanatomethyl)-4-phenylbenzene and 1-Isothiocyanato-3,5-bis(trifluoromethyl)benzene-Aldehyde Dehydrogenase (ALDH) Inhibitors, Decreases Cisplatin Tolerance and Migratory Ability of NSCLC","volume":"23","author":"Kryczka","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.amjms.2024.06.007_bib0064","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjms.2024.06.007_bib0065","doi-asserted-by":"crossref","first-page":"345","DOI":"10.12659\/AJCR.889401","article-title":"Low-dose cyclophosphamide-induced acute hepatotoxicity","volume":"14","author":"Subramaniam","year":"2013","journal-title":"Am J Case Rep"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924012783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924012783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T16:32:00Z","timestamp":1729096320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962924012783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0002962924012783"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2024.06.007","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclophosphamide in refractory autoimmune hepatitis and autoimmune hepatitis coexisting extrahepatic autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}